The Evolution of Advanced Renal Cell Carcinoma
Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
Stay updated with breaking news from Mutational Burden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...
In this fifth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, highlights progress made with regard to colon cancer treatment and Lynch syndrome, including leveraging immunotherapy.
4.3.2 Shifting Role of Diagnostics 4.3.3 Multiplexing and Foundation One 4.3.4 The Disruption Dynamic 4.3.6 The Next Five Years 5. Cancer Immuno-Oncology Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section Qiagen Expands Immuno-Oncology Portfolio IncellDx Awarded PD-L1 Detection Patent FDA Approves CDx for Trastuzumab Promega Nabs CE Mark for Microsatellite Instability IVD ArcherDx partners with AstraZeneca for Immuno-Oncology Germline Results Guides Precision Therapy ...